Numelvi®
Numelvi is the only second-generation Janus kinase (JAK) inhibitor approved for the treatment of pruritus associated with allergic dermatitis in dogs, as well as clinical manifestations associated with atopic dermatitis in dogs, including pruritus, from 6 months of age.¹
What makes Numelvi your new simple solution for itch relief?
It’s selective:
- At least 10X more selective for JAK1*¹
- Favourable safety profile¹
- Licensed for dogs as young as 6 months of age¹
It’s effective:
- Starts relieving itch within 2–4 hours**
- Once-daily dosing from day 1¹
Presentation
White to off-white oblong shaped tablets with one score-line on each side and marked with an ‘S’, ‘M’, ‘L’ or ‘XL’ according to the tablet strength.
Active ingredients
Atinvicitinib
Target species
Dogs
Indications for use
For the treatment of pruritus associated with allergic dermatitis in dogs.
For the treatment of the clinical manifestations associated with atopic dermatitis in dogs, including pruritus.
Packaging
Aluminium/PVC/polychlorotrifluoroethylene blisters containing 30 tablets per strip.
Cardboard box with 1 or 3 blister strips equivalent to 30 or 90 tablets.
Legal Category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: February 2026
References
*Over the other JAK enzymes in in vitro assays
** Based on a canine interleukin-31 induced pruritus model
1.Numelvi® Summary of product characteristics